Physician investigators are working to bring immune cellular therapies to refractory diffuse large B-cell lymphoma patients. Promising results from the phase 1 portion of the ZUMA-1 study, which uses chimeric antigen receptor (CAR) modified T cells to treat b-cell lymphoma patients, have now been published.
from Top Health News – ScienceDaily http://bit.ly/2jfOSB3
from Tumblr http://bit.ly/2hXw33X
No comments:
Post a Comment